

Amendments to the Claims:

Please enter the following amendments to claims 1 and 55:

1. (currently amended) A conjugate consisting essentially of an antibody fragment covalently modified by one or two nonproteinaceous polymer molecules at a free sulfhydryl group of a cysteine residue within the hinge region of the antibody fragment, wherein (a) the apparent molecular weight of the conjugate, as determined by size exclusion chromatography, is at least about 500 kD, (b) the average actual molecular weight of each nonproteinaceous molecule is at least 20 kD, and (c) the antibody fragment has an antigen binding site that binds human interleukin-8 (IL-8) ~~comprises~~ comprising an anti-IL-8 monoclonal antibody light chain sequence comprising amino acids 1-219 of the humanized antibody light chain 6G4.2.5v11 (SEQ ID NO: 51).

2-26. (canceled)

27. (previously presented) The conjugate of claim 1, wherein the antibody fragment is selected from the group consisting of Fab, Fab', and Fab'-SH modified by one PEG molecule having an average actual molecular weight of about 30 kD.

28-52. (canceled)

53. (previously presented) The conjugate of claim 1, wherein the antibody fragment comprises an anti-IL-8 monoclonal antibody light chain sequence comprising the amino acid sequence of humanized antibody light chain 6G4.2.5v11 (SEQ ID NO: 51).

4 ³ 54. (previously presented) The conjugate of claim ~~53~~, wherein the antibody fragment is selected from the group consisting of Fab, Fab', and Fab'-SH modified by one PEG molecule having an average actual molecular weight of about 30 kD.

5 55. (currently amended) A conjugate consisting essentially of an antibody fragment covalently modified by one or two nonproteinaceous polymer molecules at a free sulfhydryl group of a cysteine residue within the hinge region of the antibody fragment, wherein (a) the apparent molecular weight of the conjugate, as determined by size exclusion chromatography, is at least about 500 kD, (b) the average actual molecular weight of each nonproteinaceous molecule is at least 20 kD, and (c) the antibody fragment has an antigen binding site that binds human interleukin-8 (IL-8) ~~comprises comprising~~ an anti-IL-8 monoclonal antibody heavy chain sequence comprising amino acids 1-230 of the humanized antibody 6G4.2.5v11 heavy chain (SEQ ID NO: 60).

6 ⁵ 56. (previously presented) The conjugate of claim ~~55~~, wherein the antibody fragment is selected from the group consisting of Fab, Fab', and Fab'-SH modified by one PEG molecule having an average actual molecular weight of about 30 kD.

7 ³ 57. (previously presented) The conjugate of claim ~~56~~, further comprising a leucine zipper sequence.

8 ⁵ 58. (previously presented) The conjugate of claim ~~55~~, wherein the antibody fragment comprises an anti-IL-8 monoclonal antibody heavy chain sequence comprising the amino acid sequence of the humanized antibody 6G4.2.5v11 heavy chain (SEQ ID NO: 60).

9 ⁸ 59. (previously presented) The conjugate of claim ~~58~~, wherein the antibody fragment is selected from the group consisting of Fab, Fab', and Fab'-SH modified by one PEG molecule having an average actual molecular weight of about 30 kD.

10/60. (previously presented) The conjugate of claim 58, further comprising a leucine zipper sequence.